Candel Therapeutics, Inc.
CADL
$5.71
-$0.24-4.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 41.04% | -2.37% | -38.67% | -7.67% | -16.56% |
| Gross Profit | -41.04% | 2.37% | 38.67% | 7.67% | 16.56% |
| SG&A Expenses | 16.57% | 8.20% | 2.48% | 10.60% | -1.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.40% | 2.89% | -25.46% | -1.17% | -10.52% |
| Operating Income | -30.40% | -2.89% | 25.46% | 1.17% | 10.52% |
| Income Before Tax | 78.43% | 189.76% | -26.84% | -26.21% | -131.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.43% | 189.76% | -26.84% | -26.21% | -131.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.43% | 189.76% | -26.84% | -26.21% | -131.30% |
| EBIT | -30.40% | -2.89% | 25.46% | 1.17% | 10.52% |
| EBITDA | -31.40% | -3.06% | 26.08% | 1.21% | 10.93% |
| EPS Basic | 87.49% | 151.92% | -3.37% | -13.99% | -123.92% |
| Normalized Basic EPS | 87.49% | 151.93% | -1.47% | -13.99% | -123.87% |
| EPS Diluted | 87.49% | 146.16% | -3.37% | -13.99% | -123.92% |
| Normalized Diluted EPS | 87.49% | 147.84% | -1.47% | -13.99% | -123.87% |
| Average Basic Shares Outstanding | 72.33% | 72.90% | 22.71% | 10.70% | 3.31% |
| Average Diluted Shares Outstanding | 72.33% | 87.57% | 22.71% | 10.70% | 3.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |